Senseonics Holdings, Inc. (NYSE:SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today provided commercial updates related to the Eversense 365 launch.
Eversense 365 Commercial Launch Update
- Launched Eversense 365 in October with global commercial partner Ascensia Diabetes Care and began shipping product in November
- Seeing strong interest in Eversense 365, as evidenced by the following early launch performance indicators:
- Direct-to-Consumer (DTC) leads in each of October and November were more than double the number of leads in pre-launch months
- New patient shipments in November were the highest compared to any month since inception of the Ascensia partnership
- Since launch, Eversense 365 has already shown a 42% increase in the number of providers prescribing Eversense and a 69% increase in prescriptions from top prescribers compared to the pre-launch rate in 2024
- One-third of Eversense 365 prescribers are new first-time Eversense prescribers
- The number of patients switching to Eversense monthly from competitive CGMs has increased 47% since Eversense 365 launch
- Remain on-target to achieve annual growth of approximately 50% in patient installed base at the end of 2024 as compared with 2023
- Reiterated full-year 2024 global net revenue guidance of approximately $22 million
- Reiterated full-year 2024 global net revenue guidance of approximately $22 million
